

Supplementary File

Table S1. Additional patient characteristics

Pt	Comorbidities	Smoking History	Surgical procedures prior to SBRT
1	CREST syndrome, interstitial lung disease, scleroderma, Barrett's esophagus, pulmonary embolism, idiopathic cardiomyopathy	72 py, quit	12/2018 Kyphoplasty/radiofrequency ablation
2	H. pylori gastritis	7 py, quit	2014 gastrectomy
3	Asthma, epilepsy, melanoma early-stage status post local excision with no adjuvant therapy and no evidence of recurrent disease, depression	14 py, quit	2011 right middle lobectomy, axillary lymphadenectomy
4	Hypertension, kidney disease, COPD, arthritis, DM	45 py, quit	None
5	CAD status post PCI twice, HTN, HLD, PVD	100 py	None
6	COPD on O2, pneumonia, HTN, depression, back problems, endometriosis	None	None
7	Depression, anxiety, COPD, gastric ulcers, asthma, low-risk prostate cancer status post definitive radiotherapy in 2010 with no evidence of disease	None	None
8	Myocardial infarction status post stent placement, stroke, HTN	40 py, quit	None
9	Low-risk prostate cancer Gleason Score of 6 on active surveillance since 10/2007, HTN, CAD, HLD	None	10/24/2007 low anterior resection, 4/2013 lung RUL lobectomy for lung metastasis, 7/2014 attempted laparoscopy
10	HTN, HLD	120 py, quit	4/2012 tonsillar biopsy, 12/2012 right hepatic lobectomy
11	HTN, atrial fibrillation, CAD, heart murmur, chronic kidney disease, pleural effusion, benign prostatic hyperplasia, gout, HLD	None	right nephrectomy 1989, resection of local recurrence in 2002, right hepatectomy, resection of retroperitoneal masses in 2011
12	CAD status post PCI, HTN, arthritis, brain aneurysm repair, abdominal abscess	None	7/2010 lumpectomy SLNB, 7/2013 resected cerebellar metastasis
13	Pancreatitis, insulin-dependent DM, hepatitis C, GERD, intravenous drug use, HTN	None	12/2015 and 2/2016 TACE of the left hepatic artery
14	Early stage oral tongue SCC status post partial glossectomy in 2007, recurrence in 2008 status post neck dissection and chemoradiotherapy, HTN, COPD, alcoholism	unknown py, quit	10/2012 wedge resection of left lung tumor
15	Depression, anemia, pancreatitis, asthma, upper extremity thrombosis on Lovenox	None	None
16	Heart disease with cardiac arrest after being given chemotherapy, CABG in 1992 and 1997, heart valve replacement in 2011, severe COPD, HLD, alcoholism in remission	70 py	None
17	Low-risk prostate cancer status post external beam radiotherapy in 2007 with no evidence of disease recurrence, HTN, HLD, obstructive sleep apnea	None	Resection of the right temporal scalp primary, parotidectomy and right selective neck dissection
18	None	25 py	None
19	DVT, chemotherapy-induced peripheral neuropathy	30 py, quit	None
20	Renal vein and abdominal aortic thrombosis on anticoagulation, incisional hernia	5 py	None
21	Sarcoidosis, DM, gastric ulcers, depression, HTN, GERD, migraine, sleep problems, hypothyroidism, DVT	75 py, quit	Right upper lobectomy on 12/2015

Pt	Comorbidities	Smoking History	Surgical procedures prior to SBRT
22	Colitis, spinal cord injury from a motor vehicle accident status post spine surgery, history of a heart attack, COPD, claustrophobia, alcoholism	68 py	None
23	Anxiety, HTN, hypothyroidism	90 py	Nerve block in the left chest wall for pain control

Pt — patient number assigned; STFS — systemic therapy-free survival in months after adrenal SBRT; OS — overall survival at last follow-up; LC — local control in months; KPS — Karnofsky Performance Status; Smoking History — expressed in pack-years (py) current smoker unless it states “quit”; COPD — chronic obstructive pulmonary disease; DM — diabetes mellitus; CAD — coronary artery disease; PCI — percutaneous coronary intervention; HTN — hypertension; HLD — hyperlipidemia, SCC — squamous cell carcinoma; PVD — peripheral vascular disease; O2 — supplemental oxygen; GERD — gastroesophageal reflux disease; CABG — coronary artery bypass graft; DVT — deep venous thrombosis; SLNB — sentinel lymph node biopsy; TACE — transarterial chemoembolization

Supplemental table continued

Pt	Systemic therapy prior to SBRT	Radiotherapy prior to SBRT
1	None	9/2017: 16 Gy in 1 fx SBRT — T9 vertebra
2	2014: neoadjuvant cisplatin, oxaliplatin, epirubicin and 5-FU; additional treatment with ramucirumab, paclitaxel and pembrolizumab	5/2014: 12 Gy in 3 fx - GEJ, 7/2014: 45 Gy in 3 fx — liver, 10/2014: 45 Gy in 25 fx consolidation — GEJ and LN, 9/2015: Y-90 — liver lesions, 7/2016: 25 Gy in 5 fx — perigastric/periaortic LN, 7/2017 25 Gy in 5 fx — paraesophageal LN
3	2017: carboplatin and pemetrexed for recurrence; 2018 nivolumab	3/2017: 60 Gy in 30 fractions — thoracic recurrence
4	11/2015: concurrent carboplatin; additional therapy with pemetrexed and atezolizumab	11/2015: 80.4 Gy in 30 fx — thoracic disease, 1/2016: 30 Gy in 5 fx — left lung recurrence
5	Concurrent cisplatin/pemetrexed in 10/2016 to the lung primary, pembrolizumab for progression of disease; then docetaxel	10/2016: 60 Gy in 30 fx definitive lung radiotherapy
6	Carboplatin and etoposide for six cycles until 7/2016	5/2016: 30 Gy in 10 fx whole-brain radiotherapy
7	4 cycles of ipilimumab; switched to pembrolizumab for 25 cycles and then stopped due to toxicity	Lung treatment with SBRT 3000/5 for oligoprogression with hemoptysis at the same time as adrenal SBRT — alternating days
8	Carboplatin, pemetrexed and pembrolizumab in 7/2019	8 Gy in 1 fx — sternal mass
9	12 cycles of FOLFOX-6 from 6/2013 to 11/2013	None
10	4 cycles of cisplatin and etoposide 5/2012–8/2012, salvage irinotecan 9/2013; 2/2014–7/2014 capecitabine and temozolamide for of salvage lung and right adrenal metastases	8/2012: tonsillar cancer concurrent radiotherapy
11	Systemic chemotherapy in 1989 postoperatively; postoperative Interferon treatment in 2002; 22 cycles of temsirolimus until 10/2011	None
12	7/2010 4 cycles of CMF chemotherapy, 8/2013 paclitaxel for 2 cycles	7/2011: 30 Gy in 5 fx adjuvant whole breast radiotherapy; 8/2013: 21 Gy in 3 fx cerebellar metastasis postoperative cavity

Pt	Systemic therapy prior to SBRT	Radiotherapy prior to SBRT
13	Sorafenib from 6/2016 to 2/2017	None
14	None	8/2013: 50 Gy in 5 fx — left chest wall lesions
15	6 cycles of carboplatin/pemetrexed/bevacizumab from 4/2011, 4 cycles of Pemetrexed and Bevacizumab maintenance 08-12/2011, crizotinib from 7/2013; changed to certitinib until 3/2015	3/2011: stereotactic radiosurgery — brain metastasis, 11/2011: 35 Gy in 10 fx — whole brain radiotherapy; 25 Gy in 5 fx enlarged lymph node in the abdomen (not close to the adrenal SBRT site)
16	Concurrent cisplatin/etoposide with radiotherapy completed in 4/2012	4/2012: 54.9 Gy in 33 fx — lung primary concurrent chemoradiotherapy
17	Concurrent carboplatin/etoposide with radiotherapy until 7/2013	7/2013: 60 Gy in 30 fx — postoperative primary concurrent chemoradiotherapy
18	Concurrent carboplatin/etoposide with radiotherapy until 10/2014, carboplatin, paclitaxel and bevacizumab followed by maintenance bevacizumab until 12/2015; changed to pemetrexed	10/2014: 60 Gy in 30 fx concurrent chemoradiotherapy to 6000/30; 1/2015: 25 Gy in 10 fx PCI; 2/2016: 40 Gy in 10 fx — lung metastasis SBRT re-irradiation at the same time as the adrenal SBRT (alternating days)
19	Carboplatin/docetaxel (2004–2005)	6/2011: 50 Gy in 5 fx — lung recurrent disease
20	Oxaliplatin, capecitabine and bevacizumab from 6/2016 to 4/2017, HIPEC on 5/2017; pembrolizumab for recurrence started in 7/2018	8/2018: 25 Gy in 5 fx — porta hepatitis LN
21	6/2018 carboplatin, nab-paclitaxel and pembrolizumab for one cycle	4/2017: 50 Gy in 5 fx — lung
22	Carboplatin/pemetrexed	9/2017: 10-18 Gy in 1 fx - brain and dural metastases, 5/2019: 45 Gy in 10 fx - left adrenal metastasis (contralateral)
23	7/2011 4 cycles of carboplatin/pemetrexed; pemetrexed maintenance; switched to 4 cycles of carboplatin/nab-paclitaxel on 4/2017; switched to Pembrolizumab for 40 cycles	5/2019: 30 Gy in 10 fx - left chest wall mass

Pt — patient number assigned; Gy — Gray; Fx — fractions of radiation therapy; 5-FU — Fluorouracil; CMF — cyclophosphamide, methotrexate, fluorouracil; LN — lymph node; GEJ — gastroesophageal junction; Y-90 — Yttrium-90 radioembolization; PCI — prophylactic intracranial irradiation